


UChicago Medicine International Newsletter

Vol.8 / April, 2019

Dear Colleagues and Friends,

UChicago Medicine Blood Cancer Program is one of the largest programs in the US and has been at forefront of research, treatment, and national clinical trials for complex blood cancers such as Leukemia, Lymphoma and Multiple Myeloma. Especially, we are the leader in **cellular therapy** research and clinical care. We were leaders in clinical trials of two types of cellular therapy, stem cell transplants and CAR T-cell therapy, and became among the first to bring these breakthrough approaches to our patients.



In the eighth volume of UChicago Medicine International Newsletter, featured are incredible stories of our blood cancer patients who could defeat cancer with UChicago Medicine.

In addition, we are excited to announce we host [UChicago Medicine China Forum 2019](#) in Beijing on May 17th, 2019 where our cancer experts will present new research and clinical updates in leukemia and cellular therapies from UChicago Medicine. We cordially invite you and your colleagues to the forum and look forward to meeting with you all in Beijing.

FOREFRONT OF MEDICINE

[The CAR T-cell Chicago story: One year later](#)

The first patient treated at UChicago Medicine who underwent a clinical trial of CAR T-cell therapy was Scott McIntyre from Indiana. He and his doctors in his home town and at UChicago Medicine had been helping him fight DLBCL since November 2013. On May 18, 2016, he received CAR T cells — engineered by the Swiss pharmaceutical company Novartis, in partnership with the University of Pennsylvania. McIntyre is now more than 30 months post treatment as of Nov. 2018, with no sign of cancer.

[Outpatient stem cell transplant: No place like home](#)

Rebecca underwent a blood and bone marrow stem cell transplant for multiple myeloma as an outpatient spending a few hours in the outpatient unit daily, where she underwent tests and the infusion of healthy cells to overpower cancer cells, instead of the typical three- to four-week hospital inpatient stay.

[Aspiring teacher ready to spread her wings after beating leukemia](#)


Rachael, diagnosed with acute lymphoblastic leukemia, came to the Adolescent and Young Adult (AYA) Oncology Program at the University of Chicago Medicine Comer Children's Hospital. Five years after starting treatment, Rachael was cured of leukemia. Rachael graduated from college with a teaching degree and recently took a two-year position teaching middle school English in Jakarta, Indonesia.



[Dreams do come true after advanced care for lymphoma](#)

Elaine, diagnosed with large B-cell lymphoma, a type of non-Hodgkin lymphoma, got her life back to take vacations to the theme park with family, in two years after her last cancer treatment including stem cell transplant and CAR T-cell therapy at UChicago Medicine.

How CAR T-cell Therapy Works



UPCOMING EVENTS

- May 2 (Chicago) 7th International Symposium on Complex Pediatric Robotic Urological Surgery ([Link](#))
- May 4 (Chicago) At the Forefront of Hepatology ([Link](#))
- May 17 (Beijing) UChicago Medicine China Forum 2019 - Innovations in Cancer Treatment ([Link](#))
- Jun. 5-7 (Chicago) 25th Annual Primary Care Orthopaedics ([Link](#))
- Sep. 16-20 (Chicago) 2nd Annual Global Health Executive Training ([Link](#))
- Ongoing (E-Learning) UChicago Medicine E-Learning Courses ([Link](#))

If you have any question in regard to patient care, events, or international collaboration options, please contact us via email or WeChat.

Sincerely,

Nida Shekhani
Executive Director

Diala Atassi
Director

Mark Wen(温志刚)
Director for Asia

Dr. Cheng-Kai Kao (高承楷)
Medical Director

UChicago Medicine International Programs

5758 S. Maryland Ave. MC9040
Chicago IL 60026 USA
+1-773-702-0506

International.services@uchospitals.edu

<http://uchicagomedicine.org/global>



微博



微信